Posts by: Alice Melão

News

After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) ... Read more

December 6, 2019December 6, 2019

Sutro’s Investigational Antibody-Drug Conjugate Shows Promise in Advanced Ovarian Cancer Phase 1 Trial

News

STRO-002, an investigational antibody-drug conjugate being developed by Sutro Biopharma, is safe and shows promising efficacy in women with advanced ovarian, fallopian tube, or primary peritoneal cancer, early Phase ... Read more

July 26, 2019

UPMC, Helomics Join to Develop Predictive Models of Ovarian Cancer Outcomes

News

Researchers from the University of Pittsburgh Medical Center (UPMC) have teamed up with Helomics — a subsidiary of Predictive Oncology — to explore the use of artificial intelligence as ... Read more

July 3, 2019

New Blood Test May Improve Ovarian Cancer Diagnosis, Study Suggests

News

A blood test that examines a panel of 11 specific proteins could help distinguish between benign tumors and malignant ovarian cancer, reducing the need for unnecessary surgeries and leading ... Read more

June 19, 2019

Lynparza Approved in Europe as Initial Maintenance Therapy for Some OC

News

Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and ... Read more

June 12, 2019

Rubraca Maintenance Delays Disease Progression in Subsequent Treatments for Recurrent OC, Phase 3 Trial Shows

News

Maintenance treatment with Rubraca (rucaparib) delays the need for additional treatments among women with platinum-sensitive recurrent ovarian cancer — and then extends the time to disease worsening after those ... Read more

June 5, 2019June 5, 2019

Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free ... Read more

May 10, 2019

Dutch Researchers Develop Mini Ovarian Cancers to Improve Personalized Therapies

News

Dutch researchers have developed a new experimental protocol that allowed them to culture mini ovarian cancers (organoids) in the lab that retained their three-dimensional structure and captured the cellular ... Read more

April 29, 2019

Ovarian Cancer Patients Being Recruited to Test HPN536 Immunotherapy in Phase 1/2a Trial

News

Harpoon Therapeutics has begun dosing participants in its Phase 1/2a trial evaluating the investigational immunotherapy HPN536 in patients with advanced cancers that produce the mesothelin protein. The study (NCT03872206) ... Read more

April 3, 2019

DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show

News

Treatment with DPX-Survivac plus intermittent low-dose cyclophosphamide continues to show promise in women with advanced recurrent ovarian cancer, the second part of a Phase 1/2 trial shows. Interim data ... Read more

Posts by: Alice Melão

Alice Melão

NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers

Sutro’s Investigational Antibody-Drug Conjugate Shows Promise in Advanced Ovarian Cancer Phase 1 Trial

UPMC, Helomics Join to Develop Predictive Models of Ovarian Cancer Outcomes

New Blood Test May Improve Ovarian Cancer Diagnosis, Study Suggests

Lynparza Approved in Europe as Initial Maintenance Therapy for Some OC

Rubraca Maintenance Delays Disease Progression in Subsequent Treatments for Recurrent OC, Phase 3 Trial Shows

Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows

Dutch Researchers Develop Mini Ovarian Cancers to Improve Personalized Therapies

Ovarian Cancer Patients Being Recruited to Test HPN536 Immunotherapy in Phase 1/2a Trial

DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show

Pin It on Pinterest